Skip to main content

ResMed (RMD) Product Pipeline Analysis Report 2025 - ResearchAndMarkets.com

The "ResMed Inc (RMD) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

ResMed Inc (ResMed) is a medical device company. It develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders such as sleep-disordered breathing (SDB), sleep apnea and chronic obstructive pulmonary disease (COPD). Its major products include airflow generators such as continuous positive airway pressure (CPAP) devices, auto-bilevel devices, variable positive airway pressure (VPAP) devices, and automatic positive airway pressure (APAP) devices.

The company distributes its products in various countries through a combination of distributors and direct sales teams. ResMed also offers software as a service (SaaS) to out-of-hospital health providers. The company sells its products to sleep clinics, home healthcare dealers, and third-party payers. ResMed is headquartered in San Diego, California, the US.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Report Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company ResMed Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

ResMed Inc, Recent Developments

  • Dec 19, 2025: ResMed Receives FDA 510(k) Clearance for Personalized Therapy Comfort Settings (PTCS)
  • Dec 08, 2025: Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
  • Nov 19, 2025: Abigail Uttley Joins Inhealthcare as Project Manager
  • Oct 13, 2025: Fractus Files Patent Infringement Complaint Against ResMed in Southern District of California
  • Oct 01, 2025: Amy Frith Appointed Customer Success Manager for NHS Digital Health Partnerships at Inhealthcare
  • Sep 03, 2025: Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
  • Aug 21, 2025: Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
  • Aug 18, 2025: Resmed Appoints Nicole Mowad-Nassar to Board of Directors
  • Jul 21, 2025: Oxygen Therapy Devices Market Set for Steady Expansion by 2032, Driven by Fisher & Paykel Healthcare, Masimo, Vapotherm, BMC Medical, ResMed, Allied Medical, Hamilton Medical, Neote
  • Jun 10, 2025: ResMed Receives Additional 510(K) Clearance For AirFit F20

Key Topics Covered:

  • ResMed Inc Company Overview
  • ResMed Inc Company Snapshot
  • ResMed Inc Pipeline Products and Ongoing Clinical Trials Overview
  • ResMed Inc - Pipeline Analysis Overview
  • Business Description
  • ResMed Inc - Key Facts
  • ResMed Inc - Major Products and Services
  • ResMed Inc Pipeline Products by Development Stage
  • ResMed Inc Ongoing Clinical Trials by Trial Status
  • ResMed Inc Pipeline Products Overview
  • AirCurve 11 ASV - Insomnia
  • AirCurve 11 ASV - Insomnia Product Overview
  • AirCurve 11 ASV - Insomnia Clinical Trial
  • AirFit F40
  • AirFit F40 Product Overview
  • Breezhaler Inhaler - Add On Sensor
  • Breezhaler Inhaler - Add On Sensor Product Overview
  • Connected Metered Dose Inhaler
  • Connected Metered Dose Inhaler Product Overview
  • Leo
  • Leo Product Overview
  • Masksense
  • Masksense Product Overview
  • Mitigait
  • Mitigait Product Overview
  • Monterey Pneumatic Compression Device
  • Monterey Pneumatic Compression Device Product Overview
  • Personalized Therapy Comfort Settings (PTCS)
  • Personalized Therapy Comfort Settings (PTCS) Product Overview
  • Smart Device - Cardiac Health
  • Smart Device - Cardiac Health Product Overview
  • ResMed Inc - Key Competitors
  • ResMed Inc - Key Employees
  • ResMed Inc - Key Employee Biographies
  • ResMed Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Appendix

For more information about this company profile visit https://www.researchandmarkets.com/r/x0z25

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.75
-0.78 (-0.34%)
AAPL  272.72
-0.36 (-0.13%)
AMD  216.49
+1.15 (0.53%)
BAC  55.11
-0.17 (-0.31%)
GOOG  314.74
+0.19 (0.06%)
META  663.33
-2.62 (-0.39%)
MSFT  486.00
-1.48 (-0.30%)
NVDA  188.83
+1.29 (0.69%)
ORCL  196.47
-0.75 (-0.38%)
TSLA  454.82
+0.39 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.